Information about the impact of HIV treatment on viral load, the immune system, other health conditions, mortality and quality of life. The life expectancy of people living with HIV is similar to that of other people, as long as they get the right medical treatment and care.

Treatment outcomes and life expectancy: latest news

Treatment outcomes and life expectancy resources

Treatment outcomes and life expectancy features

Treatment outcomes and life expectancy in your own words

Treatment outcomes and life expectancy news from aidsmap

More news

Treatment outcomes and life expectancy news selected from other sources

  • Many Women on HIV Treatment Are at Risk of Developing a Detectable Viral Load

    An ongoing study finds that considerable challenges in such women’s lives may compromise their adherence to antiretrovirals.

    22 May 2019 | Poz
  • More than 1 year to HIV control raises failure risk almost 10-fold

    Failure to reach an undetectable viral load in the first year of antiretroviral therapy (ART) led to nearly a 10-fold higher risk of subsequent virologic failure in a 17,000-person North American analysis [1]. Taking more than 1 year to control HIV did not confer a higher risk of low-level viremia or viral blips in this 6-year study.

    15 March 2019 | NATAP
  • Up to 95% virologic response rate with rapid ART in safety-net clinic

    Up to 95% of people with newly diagnosed HIV and beginning antiretroviral therapy (ART) within a week of diagnosis reached a viral load below 50 copies in the first year of therapy. High proportions of people in this San Francisco safety-net clinic had a substance use disorder, a major mental health diagnosis, or unstable housing.

    14 March 2019 | NATAP
  • Wider ART Rollout Tied to Declines in HIV Mortality in Kenya

    Both all-cause mortality and mortality among HIV-positive people dropped in Western Kenya following a scale-up of antiretroviral therapy (ART), a researcher said here. From 2011 to 2016, all-cause mortality dropped from 10.0 per 1,000 person years (95% CI 8.4-11.7) to 7.5 per 1,000 person years (95% CI 5.8-9.1), reported Emily C. Zielinski-Gutierrez, DrPH, of the CDC.

    12 March 2019 | MedPage Today
  • Uganda: Financial incentives do not boost HIV viral suppression rate

    Financial incentives had no effect on viral suppression among HIV-positive adults in Uganda, according to a recent study. Researchers said these findings suggest a need for better interventions to promote the achievement of viral suppression.

    25 January 2019 | Healio
  • The Lisbon Patient: Meet the man living with HIV who's about to turn 100

    Referred to in a soon-to-be published case study as “The Lisbon Patient,” Miguel -- which is not his real name -- is also the oldest documented person with HIV in the world.

    18 December 2018 | CTV
  • Kenya: Riddle of gender disparities in HIV-Aids deaths

    Why are men more likely to die from HIV compared with women?

    01 December 2018 | Daily Nation
  • Navigating Mixed Messages About HIV

    We are required to both downplay the seriousness of HIV and to stress its terrible impact. Here’s the view I favor.

    08 June 2018 | Poz
  • Starting HIV treatment at diagnosis slashes drop out, drug failure rates, China study finds

    Patients diagnosed with HIV who started antiretroviral treatment within 30 days had significantly lower rates of dropping out of treatment, and higher rates successful treatment, than those who started later, particularly those who started more than three months after their diagnosis, a study in China has found.

    04 June 2018 | Science Speaks
  • Continuous Medicaid Coverage Essential for People Living With HIV

    Implementing initiatives to maintain Medicaid enrollment and expedite re-enrollment and having alternate resources available during gap times may be important to ensure continuous antiretroviral therapy (ART) to optimize HIV outcomes, according to a study recently published in the Journal of Acquired Immune Deficiency Syndromes.

    01 June 2018 | Infectious Disease Advisor
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.